JCP Editors

Clearance of Somatic Mutations and the Effect on Risk of Relapse in AML

Clearance of somatic mutation at complete remission is associated with significantly better survival in patients with acute myeloid leukemia.

Read More

 

AML Immune Profile Linked With Relapse-Free Survival

The conference theme was keeping patients and their needs paramount in transforming the US cancer care system.
The conference—which focuses on improving the quality, effectiveness, and efficiency of cancer care—hosts over 1600 national and international academic and community oncologists, oncology fellows, nurses, pharmacists, and other health care professionals involved in cancer care.
The SGO Annual Meeting on Women’s Cancer brings together gynecologic oncologists from all over the world to share the latest research and practice innovations in the treatment of gynecologic malignancies.

Texas Oncology, Aetna Collaborate to Improve Patient Care Through Clinical Pathways

Texas Oncology and Aetna partnered to provide a practice-based program that reduced costs while maintaining adherence to treatment pathways and patient satisfaction in Medicare patients.

Read More

 

The American Society of Clinical Oncology Cancer Survivorship Symposium provided information about survivorship issues that both oncologists and primary care physicians are faced with throughout the cancer care continuum.
The 2018 American Society of Clinical Oncology Genitourinary Cancers Symposium provides a forum for physicians and other members of the oncology care and research community who diagnose, treat, and study genitourinary malignancies.

ASCO Releases Review of Prominent Commercial Clinical Pathway Vendors

The American Society of Clinical Oncology Task Force assessed 6 national pathway vendors to compare their products against the ASCO Criteria for High-Quality Clinical Pathways.

Read More

 

The GI Cancers Symposium is a specialized oncology event designed to provide scientific and educational content for members of the GI cancer care and research community.

Real-World Outcomes of Patients With NSCLC Treated With PD-1 Inhibitors After Approval

Certain subgroups of patients with NSCLC are underrepresented in clinical trials for newly approved PD-1 inhibitors and are needed to inform real-world treatment decisions.

Read More